Cara Therapeutics, Inc. (CARA)
Market Cap | 15.19M |
Revenue (ttm) | 16.94M |
Net Income (ttm) | -122.54M |
Shares Out | 54.68M |
EPS (ttm) | -2.26 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 653,829 |
Open | 0.274 |
Previous Close | 0.263 |
Day's Range | 0.265 - 0.291 |
52-Week Range | 0.240 - 3.450 |
Beta | 0.79 |
Analysts | Hold |
Price Target | 1.00 (+259.84%) |
Earnings Date | Aug 5, 2024 |
About CARA
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruish... [Read more]
Financial Performance
In 2023, CARA's revenue was $20.97 million, a decrease of -49.92% compared to the previous year's $41.87 million. Losses were -$118.51 million, 38.7% more than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CARA stock is "Hold." The 12-month stock price forecast is $1.0, which is an increase of 259.84% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/m/i/biotech25-2478433.jpg)
These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'
Shares of Cara Therapeutics Inc CARA tanked in early trading on Thursday, with the Dow shedding more than 100 points.
![](https://cdn.snapi.dev/images/v1/3/k/urlhttps3a2f2fgfoolcdncom2fedi-2476651.jpg)
Cara Therapeutics discontinues study on a neurological condition as drug fails
Cara Therapeutics said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its experimental drug did not demonstrate a meaningful clinical...
![](https://cdn.snapi.dev/images/v1/q/x/press19-2476548.jpg)
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June ...
![](https://cdn.snapi.dev/images/v1/g/p/press19-2427992.jpg)
Cara Therapeutics Reports First Quarter 2024 Financial Results
Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24 Topline efficacy and safety results from KOURAGE 1 Part ...
![](https://cdn.snapi.dev/images/v1/n/f/conf14-2411484.jpg)
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...
![](https://cdn.snapi.dev/images/v1/y/c/new-mj-news-pic-2352104.jpg)
Cara Therapeutics, Inc. (CARA) to Present at the 23rd Annual Needham Virtual Healthcare Conference
Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Ch...
![](https://cdn.snapi.dev/images/v1/w/b/conf19-2351551.jpg)
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patie...
![](https://cdn.snapi.dev/images/v1/z/b/press13-2312716.jpg)
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patie...
![](https://cdn.snapi.dev/images/v1/x/h/press1-2307249.jpg)
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)–
![](https://cdn.snapi.dev/images/v1/b/f/conf6-2272248.jpg)
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:...
![](https://cdn.snapi.dev/images/v1/r/v/press11-2237893.jpg)
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need –
![](https://cdn.snapi.dev/images/v1/f/x/press11-2199709.jpg)
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
– Oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in pruri...
![](https://cdn.snapi.dev/images/v1/z/g/press12-2155437.jpg)
Cara Therapeutics Reports Third Quarter 2023 Financial Results
– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 –
![](https://cdn.snapi.dev/images/v1/t/0/press4-2135526.jpg)
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
Transaction supports progression of late-stage oral difelikefalin clinical programs Non-dilutive capital expected to extend cash runway into 2025 STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Car...
![](https://cdn.snapi.dev/images/v1/l/5/conf17-2114808.jpg)
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
STAMFORD, Conn., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...
![](https://cdn.snapi.dev/images/v1/q/f/press18-2075925.jpg)
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
STAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien...
![](https://cdn.snapi.dev/images/v1/1/t/press9-2010434.jpg)
Cara Therapeutics Reports Second Quarter 2023 Financial Results
– 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company's share of profit of KORSUVA ® (difelikefalin) injection –
![](https://cdn.snapi.dev/images/v1/q/i/press18-2003897.jpg)
Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...
![](https://cdn.snapi.dev/images/v1/d/e/conf2-2000939.jpg)
Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...
![](https://cdn.snapi.dev/images/v1/g/z/conf15-1983871.jpg)
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...
![](https://cdn.snapi.dev/images/v1/g/w/conf20-1915998.jpg)
Cara Therapeutics to Present at the Jefferies Healthcare Conference
STAMFORD, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...
![](https://cdn.snapi.dev/images/v1/x/i/press1-1896556.jpg)
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in ad...
![](https://cdn.snapi.dev/images/v1/c/m/press14-1890857.jpg)
Cara Therapeutics Reports First Quarter 2023 Financial Results
– 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company's share of profit of KORSUVA ® (difelikefalin) injection –
![](https://cdn.snapi.dev/images/v1/p/a/biotech2-1863157.jpg)
Cara Therapeutics, Inc. (CARA) to Announce First Quarter 2023 Financial Results on May 15, 2023
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15,
![](https://cdn.snapi.dev/images/v1/l/f/conf17-1862672.jpg)
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
STAMFORD, Conn., May 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients...